Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Radionuclide particle implantation medicine for cancer, use and preparation method thereof

A particle and nuclide technology, which is applied in the field of implantation of nuclide particles for cancer treatment, can solve the problems of inability to exert anti-cancer effects, short drug action time, and limited treatment intensity, so as to reduce systemic side effects and standardize treatment. , improve the effect of survival

Inactive Publication Date: 2010-12-08
江苏三和生物工程股份有限公司 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Slow-release chemotherapeutic particle implants: fluorouracil-PLLA has similarities with the present invention, and its advantage is that it can increase the local drug concentration and prolong the time for the chemotherapeutic drug to act on cancer cells, but the anti-cancer effect cannot be exerted if the drug is not released. There are still shortcomings such as short drug action time and drug resistance, and the improvement of treatment intensity is limited. Currently, it is used clinically to assist radioactive particle therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Radionuclide particle implantation medicine for cancer, use and preparation method thereof
  • Radionuclide particle implantation medicine for cancer, use and preparation method thereof
  • Radionuclide particle implantation medicine for cancer, use and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] A nuclide particle implant drug for cancer treatment: a composition formed by mixing a radionuclide capable of emitting beta rays and a biodegradable polymer material, the proportion of which is high in biodegradability per 0.9-1.1mg The molecular material is equipped with a radionuclide capable of emitting β-rays with a radioactivity of 18.5-37 MBq. In this embodiment, the radionuclide capable of emitting β-rays with a radioactivity of 18.5-37 MBq and a mass of 0.9-1.1 mg of biodegradable polymer materials can be mixed, or can be mixed according to the above ratio, and the ratio can be specifically selected as: every 0.9 mg of biodegradable polymer materials is mixed with a radioactive activity of 18.5MBq capable of emitting β radioactive nuclides; every 0.9 mg of biodegradable polymer material is equipped with a radionuclide that can emit β rays with a radioactivity of 37MBq; every 1.0mg of biodegradable polymer material is equipped with a radioactivity of 28MBq The r...

Embodiment 2

[0049] A nuclide particle implant drug for cancer treatment, the implant drug is composed of a mixture of radionuclide capable of emitting beta rays and a biodegradable polymer material, the proportion of which is 0.9-1.1 mg of biodegradable The active polymer material is equipped with a radionuclide capable of emitting β-rays with a radioactivity of 18.5-37MBq. In this embodiment, the radionuclide capable of emitting β-rays with a radioactivity of 18.5-37MBq and a mass of 0.9 ~1.1mg of biodegradable polymer materials can be mixed, or can be mixed according to the above ratio. Beta-ray-emitting radionuclides; every 0.9mg of biodegradable polymer materials with a radioactivity of 37MBq can emit beta-ray radionuclides; every 0.95mg of biodegradable polymer materials with radioactivity 25MBq of radionuclides capable of emitting β-rays, or, every 1.1mg of biodegradable polymer materials are mixed with radionuclides of 37MBq of radioactive activity capable of emitting β-rays.

[0...

Embodiment 3

[0054] 32 Application of P-CP and poly-L-lactic acid composition as nuclide particle implantation drug for treating malignant solid tumors.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the drug implant of radionuclide particles for cancer therapy. The drug implant comprises composition which is composed of radionuclide which can emit Beta rays, and biodegradable high-molecular material. The compounding ratio is as follows: each 0.9-1.1 mg of the biodegradable high molecular material is proportional to radionuclide which can emit Beta rays with the radioactivity of 18.5 to 37.0 MBq. The composition of <32>P-CP and poly-L-lactic acid is taken as the drug implant of the radionuclide particles for the therapy of malignant solid tumors. The preparation method comprises the following steps: selecting colloidal chromic phosphate or calcium phosphate with the radioactive concentration of 3700 to 7400 MBq / ml and the chemical concentration of 0.5 to 4.14 mg / mal as the <32>P-CP, according to the proportion that <32>P-CP: PLLA is 18.5 to 37.0 MBq: 0.9 to 1.1 mg and according to the proportion that each gram of poly-L-lactic acid is proportional to 3 to 6 ml of anhydrous alcohol, adding anhydrous alcohol into the poly-L-lactic acid and mixing, then adding the <32>P-CP and mixing uniformly, obtaining the paste composition, grinding the paste composition to uniformly distribute the radioactivity into the medium, drying the composition at 60 DEG C to 70 DEG C, then further grinding the composition into powder, positioning the powder into a pressing machine, and pressing particles with the diameter of 0.8 to 1 mm and the length of 2 to 4 mm.

Description

Technical field: [0001] The invention belongs to the technical field of tumor nuclear medicine, and in particular relates to a medicine for implanting nuclide particles for treating cancer, its application and its preparation method. Background technique: [0002] radiopharmaceutical colloid 32 P-chromic phosphate (chromic phosphate, 32 P-CP) is the radionuclide used in the present invention, which is a nanoscale colloid solution and belongs to an inert substance. Injected into the body cavity, most of it stays at the injection site, or evenly adheres to the inner wall of the body cavity and the surface of the tumor tissue, or is swallowed by the phagocytes of the reticuloendothelial system in the lymphatic vessels and lymph nodes near the tumor, resulting in more concentrated radioactive colloids In and near tumor lesions, the indication is for the control of cancerous pleural effusion and adjuvant therapy for certain malignant tumors. Our previous study by interstitial ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K51/00A61K51/06A61P35/00A61K103/00A61K103/30
Inventor 刘璐黄培林王自正陈大明杨敏高海林聂琦黄鹰
Owner 江苏三和生物工程股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com